Park Hyo Song, Park Sung Chul, Kim Jin Ha, Ohn Young Hoon, Park Tae Kwann, Han Jung Woo
Department of Ophthalmology, Soonchunhyang University College of Medicine, Cheonan, Republic of Korea.
Department of Ophthalmology, Soonchunhyang University Hospital Bucheon, Bucheon, Republic of Korea.
Ophthalmol Ther. 2025 May 14. doi: 10.1007/s40123-025-01153-8.
The retropupillary iris-claw intraocular lens (RP-IOL) offers a sutureless solution to complications like aphakia, intraocular lens (IOL) dislocation, and opacification post-cataract surgery. Unlike time-consuming, complication-prone traditional methods, RP-IOL potentially reduces surgical time and complications. This study evaluates RP-IOL's clinical outcomes to assess its efficacy and safety.
This single-center retrospective case series reviewed medical records of 68 eyes from 68 patients who underwent RP-IOL implantation between January 2017 and May 2023. Preoperative and postoperative data, including visual acuity (VA), intraocular pressure (IOP), and spherical equivalent (SE), were analyzed.
The mean uncorrected VA improved significantly from 1.25 ± 0.73 (logarithm of the minimum angle of resolution) preoperatively to 0.42 ± 0.47 at 1 month postoperatively (P < 0.001). The mean IOP decreased significantly from 17.69 ± 5.01 mmHg preoperatively to 16.09 ± 4.23 mmHg 1 month postoperatively (P = 0.041). Postoperative complications occurred in 35.3% of cases, with the most common being IOP elevation (13.2%), cystoid macular edema (11.8%), and disenclavation of IOL (7.4%). Most complications were successfully managed. The study also included a subanalysis of seven patients with IOL opacification, showing improved VA postoperatively, although without statistical significance due to the small sample size.
RP-IOL implantation is an effective and safe option for secondary IOL implantation or exchange in cases of aphakia, IOL dislocation, and IOL opacification. The procedure offers significant improvements in visual acuity and a reduction in intraocular pressure, with manageable postoperative complications. While the study supports the use of RP-IOL as a viable option, further research with larger sample sizes and prospective designs is recommended to establish its long-term efficacy and safety compared to traditional methods.
瞳孔后虹膜爪型人工晶状体（RP-IOL）为无晶状体、人工晶状体（IOL）脱位和白内障手术后混浊等并发症提供了一种无缝合解决方案。与耗时且易出现并发症的传统方法不同，RP-IOL有可能减少手术时间和并发症。本研究评估RP-IOL的临床结果以评估其有效性和安全性。
本单中心回顾性病例系列研究回顾了2017年1月至2023年5月期间接受RP-IOL植入的68例患者68只眼的病历。分析术前和术后数据，包括视力（VA）、眼压（IOP）和等效球镜度（SE）。
平均未矫正视力从术前的1.25±0.73（最小分辨角对数）显著提高到术后1个月时的0.42±0.47（P<0.001）。平均眼压从术前的17.69±5.01mmHg显著降低到术后1个月时的16.09±4.23mmHg（P=0.041）。35.3%的病例发生术后并发症，最常见的是眼压升高（13.2%）、黄斑囊样水肿（11.8%）和IOL脱离（7.4%）。大多数并发症得到成功处理。该研究还对7例IOL混浊患者进行了亚分析，结果显示术后视力有所改善，尽管由于样本量小无统计学意义。
对于无晶状体、IOL脱位和IOL混浊病例的二期IOL植入或置换，RP-IOL植入是一种有效且安全的选择。该手术可显著提高视力并降低眼压，术后并发症可控。虽然本研究支持将RP-IOL作为一种可行的选择，但建议进行更大样本量和前瞻性设计的进一步研究，以确定其与传统方法相比的长期有效性和安全性。
